A New Way to Contain Unaffordable Medication Costs - Exercising the Government's Existing Rights

N Engl J Med. 2022 Mar 24;386(12):1104-1106. doi: 10.1056/NEJMp2117102. Epub 2022 Feb 9.

Authors

Alfred B Engelberg¹, Jerry Avorn¹, Aaron S Kesselheim¹

Affiliation

¹ From the Engelberg Foundation, Palm Beach, FL (A.B.E.); and the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School - both in Boston (J.A., A.S.K.).

PMID: 35139270
DOI: 10.1056/NEJMp2117102

No abstract available

MeSH terms

Drug Costs / legislation & jurisprudence*
Drug Industry / legislation & jurisprudence
Drugs, Generic*
Federal Government
Humans
Legislation, Drug*
Patents as Topic / legislation & jurisprudence*
Prescription Fees / legislation & jurisprudence
United States
United States Food and Drug Administration

Substances

Drugs, Generic